yl23455永利官网

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2200056203】Effect of Transcranial Direct Current Stimulation (tDCS) on Improving Inhibitory Control and Working Memory in Children with Attention-Deficit / Hyperactivity Disorder (ADHD) and comorbid Autism Spectrum Disorder (ASD) – A Randomised Controlled Trialutism Spectrum Disorder (ASD) – A Randomised Controlled Trial

    基本信息
    登记号

    ChiCTR2200056203

    试验状态

    正在进行

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2022-02-01

    临床申请受理号

    /

    靶点

    /

    适应症

    多动症(ADHD)和自闭症(ASD)

    试验通俗题目

    Effect of Transcranial Direct Current Stimulation (tDCS) on Improving Inhibitory Control and Working Memory in Children with Attention-Deficit / Hyperactivity Disorder (ADHD) and comorbid Autism Spectrum Disorder (ASD) – A Randomised Controlled Trialutism Spectrum Disorder (ASD) – A Randomised Controlled Trial

    试验专业题目

    Effect of Transcranial Direct Current Stimulation (tDCS) on Improving Inhibitory Control and Working Memory in Children with Attention-Deficit / Hyperactivity Disorder (ADHD) and comorbid Autism Spectrum Disorder (ASD) – A Randomized Controlled Trial

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    The primary objective of the study is to evaluate the effect of tDCS on inhibitory control and working memory in primary school-aged children with ADHD and comorbid ASD immediately after the intervention and 1-week post-intervention. The secondary objectives of the study include: 1. To compare the effect of tDCS on clinical symptoms of ADHD and ASD between the intervention group and control group at 1 week post-intervention. 2. To evaluate the safety profile of tDCS and describe any adverse events of tDCS in children with ADHD and comorbid ASD.

    试验分类
    试验类型

    随机平行对照

    试验分期

    其它

    随机化

    The subjects will be randomly allocated to the intervention group or the control group by a block randomization procedure with 1:1 group allocation. Allocation concealment will be adopted to prevent selection bias. The randomization sequence will be electronically generated.

    盲法

    Not stated

    试验项目经费来源

    The Chinese University of Hong Kong

    试验范围

    /

    目标入组人数

    20

    实际入组人数

    /

    第一例入组时间

    2021-11-29

    试验终止时间

    2022-06-30

    是否属于一致性

    /

    入选标准

    1. Age of 6 - 12 years old; 2. Right-handed； 3. With a diagnosis of ADHD and comorbid ASD made based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) by a Psychiatry specialist; 4. Able to understand spoken instructions in Cantonese and read written traditional Chinese; 5. Studying in mainstream school; 6. Currently not taking stimulant medications (Methylphenidate or Lisdexamfetamine), or agree to stop stimulant medications starting from 72 hours before the first stimulation and until one week after the last stimulation.；

    排除标准

    1. History of significant head trauma or skull defects; 2. Implanted with pacemakers, intracranial electrodes, defibrillators, or other metallic implants; 3. Neurological conditions including but not limited to seizure, stroke, intracranial tumors or aneurysms; 4. Sensory or motor impairments; 5. Documented history of Intellectual Disability; 6. Currently on psychotropics other than stimulants or other CNS drugs；

    研究者信息
    研究负责人姓名
    试验机构

    nil

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    nil的其他临床试验

    更多

    香港中文大學的其他临床试验

    更多

    最新临床资讯

    yl23455永利官网企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品